UCB has presented the first pooled data analysis from phase 3 trials of its bimekizumab treatment for moderate to severe hidradenitis suppurativa at the European Academy of Dermatology and Venereology (EADV) Congress. The analysis showed the treatment led to clinically important improvements and a large percentage of patients who achieved a high skin response after 16 weeks maintained their response up to 48 weeks.
M&S still rebuilding after April cyber incident – Digital Watch Observatory
Summarize this content to a maximum of 60 words: M&S still rebuilding after April cyber incident Digital Watch Observatory
